Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio 25
- Development stage
- Phase 4
- Lead developer
- Ambrosia-SupHerb
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bio 25 is a high-potency, multi-strain probiotic dietary supplement manufactured by the Israeli company Supherb. It contains 11 distinct strains of beneficial bacteria, including species from the *Lactobacillus* and *Bifidobacterium* genera, with a concentration of 25 billion active organisms per capsule. The formulation is designed to restore and maintain a healthy balance of gut microbiota. In clinical research, specifically a Phase 4 trial at The Baruch Padeh Medical Center, Poriya, Bio 25 has been evaluated for its ability to improve recovery rates and reduce inflammatory markers in patients with Crohn's disease exacerbations. The supplement is intended to modulate the intestinal immune response and support mucosal barrier integrity.
- Brand names
- Bio 25Bio25Bio-25
- Other names
- Supherb Bio 25
Beyond the preview
Go deeper on Bio 25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio 25.